$CBIO

$12.76 -$0.06 (0.47%) Close

$CBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 37.1M shares outstanding

Who owns CBIO?

By type of holder

Institutions 79.7% Insiders 0.0% Everyone else 20.3%

Concentration Top 10 holders own 99.1%

Peter Harwin 17.8% · Fairmount Healthcare Fund II L.P. 17.8%

Institutional ownership

79.7%

+9.8 pts vs last qtr

Institutional holders

+19 vs last qtr

Net shares bought

+3.6M

by institutions in Q2 2026

New / sold out

31 / 12

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Logos Global Management LP +1.4M
BlackRock, Inc. +1.2M

Biggest sellers in Q2 2026

Deep Track Capital, LP SOLD OUT −453.7K
Alyeska Investment Group, L.P. SOLD OUT −264.0K

Who is planning to sell?

Notices of proposed sale, last 12 months

$279K

4 notices from 2 people

Shares covered

16.0K

0.04% of the company

Arranged in advance

100%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Joshua T Brumm Officer 10b5-1 $188K
Jonathan McNeill Officer 10b5-1 $91K

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2019–FY2024

+49.1%

+8.31% a year

Each share's claim on the business

−32.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $31.3M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years14% 3–5 years0% 1–3 years44% Under 1 year43%

Quarterly turnover

13.6%

of institutional shares changed hands

Top 10 managers, median time held

1 year

Super Investors

Investment managers reporting CBIO on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
F FMR LLC	4.1M	11.13%	Unchanged	2025	0.0%
Shares held by quarter Peak holding4.1M (Q4'25) Change over 8 quarters+4.1M Share of the company11.130% FMR LLC's full portfolio →
BI BVF Inc/il	2.7M	7.40%	Unchanged	≤2021	1.3%
Shares held by quarter Peak holding9.5M (Q3'24) Change over 8 quarters−6.8M Share of the company7.400% BVF Inc/il's full portfolio →

FMR LLC

4.1M

% of company

11.13%

Change vs last qtr

Unchanged

Held since

2025

BVF Inc/il

2.7M

% of company

7.40%

Change vs last qtr

Unchanged

Held since

≤2021

28 more super investors behind a free account

See every manager holding Crescent Biopharma Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting CBIO on Form N-PORT; together they hold 2.3% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$11.9M	661.9K	1.78%	0.00%	June 30, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$1.51M	83.8K	0.23%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$11.9M

% of company

1.78%

% of the fund

0.00%

As of

June 30, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$1.51M

% of company

0.23%

% of the fund

0.00%

As of

June 30, 2026

18 more funds behind a free account

See every fund holding Crescent Biopharma Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
PH Peter Harwin 5%+ holder 13D · 16.5%	6.6M	17.78%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company17.780% Disclosed stake13D · 16.5% View the 13D/G filing →
FH Fairmount Healthcare Fund II L.P. 5%+ holder 13D · 16.5%	6.6M	17.75%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company17.750% Disclosed stake13D · 16.5% View the 13D/G filing →

Peter Harwin

5%+ holder13D · 16.5%

6.6M

% of company

17.78%

Change vs last qtr

—

Held since

—

Fairmount Healthcare Fund II L.P.

5%+ holder13D · 16.5%

6.6M

% of company

17.75%

Change vs last qtr

—

Held since

—

4 more holders behind a free account

See every insider and 5%+ holder of Crescent Biopharma Inc.

Comments